Elanco Completes Bayer Animal Health Acquisition

Ticker: ELAN · Form: 8-K · Filed: 2024-07-09T00:00:00.000Z

Sentiment: neutral

Topics: acquisition, completion, animal-health

TL;DR

Elanco just bought Bayer's animal health business, big move for the sector.

AI Summary

Elanco Animal Health Incorporated announced the completion of its acquisition of Bayer Animal Health on July 9, 2024. This strategic move is expected to significantly enhance Elanco's portfolio and market position in the animal health industry.

Why It Matters

This acquisition is a major step for Elanco, potentially reshaping the competitive landscape of the animal health market and impacting product availability and innovation.

Risk Assessment

Risk Level: medium — The integration of a large acquisition carries inherent risks related to operational synergy, market reception, and potential regulatory hurdles.

Key Players & Entities

FAQ

What was the exact date of the completion of the acquisition?

The acquisition was completed on July 9, 2024.

What is the name of the company filing this report?

The company filing this report is Elanco Animal Health Incorporated.

In which state is Elanco Animal Health Incorporated incorporated?

Elanco Animal Health Incorporated is incorporated in Indiana.

What is the principal executive office address of Elanco Animal Health Incorporated?

The principal executive office is located at 2500 Innovation Way, Greenfield, Indiana 46140.

What is the telephone number for Elanco Animal Health Incorporated?

The telephone number is (877) 352-6261.

From the Filing

0001104659-24-078464.txt : 20240709 0001104659-24-078464.hdr.sgml : 20240709 20240709083021 ACCESSION NUMBER: 0001104659-24-078464 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240709 ITEM INFORMATION: Completion of Acquisition or Disposition of Assets ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240709 DATE AS OF CHANGE: 20240709 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elanco Animal Health Inc CENTRAL INDEX KEY: 0001739104 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 825497352 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38661 FILM NUMBER: 241106398 BUSINESS ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 BUSINESS PHONE: 877-352-6261 MAIL ADDRESS: STREET 1: 2500 INNOVATION WAY CITY: GREENFIELD STATE: IN ZIP: 46140 8-K 1 tm2419092d1_8k.htm 8-K false 0001739104 0001739104 2024-07-09 2024-07-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES   SECURITIES AND EXCHANGE COMMISSION WASHINGTON , D. C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934     Date of Report (Date of Earliest Event Reported): July 9, 2024   Elanco Animal Health Incorporated (Exact name of registrant as specified in its charter)   Indiana   001-38661   82-5497352 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   2500 Innovation Way Greenfield , Indiana (Address of principal executive offices)   46140 (Zip Code)   Registrant’s telephone number, including area code: ( 877 ) 352-6261   Not Applicable (Former Name or Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):   ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, no par value   ELAN   New York Stock Exchange   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   ¨  Emerging growth company   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨           Item 2.01. Completion of Acquisition or Disposition of Assets.   As previously disclosed, on February 5, 2024, Elanco Animal Health Incorporated, an Indiana corporation (“Elanco”) entered into an Asset Purchase Agreement (as amended, modified or supplemented from time to time, the “Purchase Agreement”) with Intervet International B.V., a Dutch private company with limited liability (“Buyer”), pursuant to which Buyer agreed to, subject to the satisfaction or waiver of certain conditions, acquire assets of Elanco’

View on Read The Filing